Eli Lilly (NYSE:LLY) Gains FDA Approval for EBGLYSS, Expands …
WEB1 day ago · Eli Lilly(NYSE:LLY) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a robust 36% surge in Q2 revenue, driven by new product launches ...
Eli Lilly and Company (LLY) - Yahoo Finance
WEBGet the latest Eli Lilly and Company (LLY) stock news and headlines to help you in your trading and investing decisions.
Lilly expands manufacturing footprint in Ireland with $1.8 billion ...
WEBINDIANAPOLIS, Sept. 12, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a $1 billion expansion of its Limerick, Ireland, manufacturing site to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease.
Eli Lilly and Company (LLY) Latest Press Releases & Corporate News …
WEBGet the latest Eli Lilly and Company (LLY) stock news and headlines to help you in your trading and investing decisions.
Lilly.com | Eli Lilly and Company
WEBINDIANAPOLIS , Sept. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member of the company's …
All News - Eli Lilly and Company
WEBLilly's latest press releases, stories, news resources and more.
Lilly hits record high after Mounjaro fuels forecast raise, rival data
WEBAug 8, 2023 · Eli Lilly on Tuesday raised its annual forecasts as demand for new diabetes drug Mounjaro surges ahead of a decision on its use as a weight-loss treatment, with shares soaring 18% to a record...
News Release - Eli Lilly and Company
WEBFDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. May 13, 2022. Download PDF. Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials.
News Release - Eli Lilly and Company
WEBINDIANAPOLIS, April 17, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints.
FDA advisers endorse Eli Lilly’s early-stage Alzheimer’s drug ... - CNN
WEBJun 11, 2024 · On Monday, a panel of independent advisers to the US Food and Drug Administration voted to endorse Eli Lilly’s drug donanemab, a monoclonal antibody designed to slow the progression of...
- Some results have been removed